M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Boehringer Ingelheim and Lilly Diabetes alliance awarded European Commission's approval for third diabetes tablet Jardiance
Pharmaceutical company Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company (NYSE:LLY) reported on Friday the receipt of the European Commission's marketing authorisation for Jardiance tablets for the treatment of type 2 diabetes mellitus (T2D) in adults in Europe.
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives